福州地区无偿献血人群新冠疫苗加强免疫与突破性感染后特异性抗体消长情况分析  

Serological follow-up of anti-SARS-CoV-2 antibodies in blood donors after COVID-19 vaccine booster dose and breakthrough infections in Fuzhou

作　　者：纪淑华[1] 林授[1] 黄淑铭[1] 林小枚 张宇 江伟梅[1] 褚晓凌[1] JI Shuhua;LIN Shou;HUANG Shuming;LIN Xiaomei;ZHANG Yu;JIANG Weimei;CHU Xiaoling(Fujian Blood Center,Fuzhou 350004,China;Clinical Laboratory,Mengchao Hepatobiliary Hospital of Fujian Medical Univesity.)

机构地区：[1]福建省血液中心,福建福州350004 [2]福建医科大学孟超肝胆医院检验科

出　　处：《中国输血杂志》2023年第12期1089-1094,共6页Chinese Journal of Blood Transfusion

基　　金：福建省科技厅社会发展引导性(重点)项目(2021Y0098)。

摘　　要：目的通过对福州地区无偿献血人群新冠病毒灭活疫苗第1剂加强免疫前后以及突破性感染后特异性SARS-COV-2 IgG抗体水平的监测,分析抗体消长特性,为新冠特免血浆或康复者恢复期血浆采集和后续疫苗接种时机提供依据。方法从福建省血液中心2021年10—11月无偿献血者中招募并随访接受第1剂新冠疫苗加强免疫的志愿者109名和发生突破性感染者102名。分别在加强免疫前14(11,20)d(Time0)、加强免疫后14(10,23)d(Time1)、53(45.5,61)d(Time2)、88(78,101.5)d(Time3)、124(112.5,138.5)d(Time4)、158(146,174)d(Time5)、194(179.5,214)d(Time6)、发生突破性感染后1个月内(Time7)留取血液标本,共8次。采用化学发光免疫分析法检测SARS-COV-2 IgG抗体水平,分析抗体消长情况及不同年龄、性别、体重、血型、BMI、吸烟的影响。结果Time0、Time1、Time6 SARS-COV-2IgG抗体阳性率分别为53.2%(58/109)、100%(109/109)和95.4%(104/109),Time1和Time6抗体阳性率和抗体值均高于Time0,差异有统计学意义(P<0.001)。Time1 IgG抗体水平最高,此后逐月下降,Time2~Time6水平分别为峰值的89.9%(9.74/10.84)、77.7%(8.42/10.84)、68.3%(7.4/10.84)、59.4%(6.44/10.84)、53.9%(5.84/10.84)(P<0.001),不同性别、体重、BMI、年龄、血型、是否吸烟组同时间点的IgG抗体水平差异无统计学意义(P值均>0.05)。Time7 IgG抗体水平达Time1时的2.07倍(P<0.001),无症状组与有症状组、无发热组与发热组抗体水平差异无统计学意义(P值均>0.05),无突破性感染组和突破性感染组抗体水平差异有统计学意义(P<0.001)。结论新冠疫苗接种和包括新冠病毒感染在内的多次抗原暴露可刺激机体产生更强的免疫应答,新冠病毒疫苗加强免疫或突破性感染1月左右进行新冠特免血浆或康复者恢复期血浆采集为佳。应持续监测抗体消长情况,为后续疫苗接种时机提供依据。Objective To analyze the dynamics of specific SARS-CoV-2 IgG antibodies in blood donors in Fuzhou area after receiving booster doses of inactivated COVID-19 vaccine and breakthrough infections,and to provide evidence for the timing of the collection of specific immune plasma or convalescent plasma and the subsequent vaccine doses.Methods A total of 109 volunteers who received the first booster dose of inactivated COVID-19 vaccine and 102 volunteers who experienced breakthrough infections were recruited at Fujian Blood Center from October to November 2021.Blood samples were collected at eight time points:14(11,20)days before the booster dose(Time0),14(10,23)days after the booster dose(Time1),53(45.5,61)days after the booster dose(Time2),88(78,101.5)days after the booster dose(Time3),124(112.5,138.5)days after the booster dose(Time4),158(146,174)days after the booster dose(Time5),194(179.5,214)days after the booster dose(Time6)and within one month after the breakthrough infection(Time7).Serum SARS-CoV-2 IgG antibodies were detected using a chemiluminescence immunoassay.The dynamics of antibody levels were analyzed and the effects of age,gender,weight,BMI,blood type and smoking on antibody levels were also analyzed.Results The positive rate of SARS-CoV-2 IgG antibodies was 53.2%(58/109)at Time0,100%(109/109)at Time1,and 95.4%(104/109)at Time6.The antibody levels were significantly higher at Time1 and Time6 than at Time0(P<0.001).The highest level was observed at Time1,followed by a gradual decrease until Time2-Time6,which were 89.9%(9.74/10.84),77.7%(8.42/10.84),68.3%(7.4/10.84),59.4%(6.44/10.84),and 53.9%(5.84/10.84)of the peak value at Time1(P<0.001).There were no significant differences in IgG antibody levels among different gender,weight,BMI,age,blood type and smoker or non-smoker at the same time points(P values all>0.05).The IgG antibody level at Time7 was 2.07 times than that at Time1(P<0.001).There were no significant differences in IgG antibody levels between asymptomatic groups and symptomatic groups and a

关 键 词：新型冠状病毒 疫苗 抗体 突破性感染 福州 

分 类 号：R457.1[医药卫生—治疗学] S852.43[医药卫生—临床医学]